Fore Pharmas latest report ‘Global Muscular Atrophy Drug Pipeline Capsule – 2011 is an outline of all the key research and development (R&D) activities of the global muscular atrophy drug market. It covers information on key pipeline molecules in various stages of R&D including all the phases of clinical trials, preclinical research, and drug discovery. The report is up-to-date with full coverage of the licensing activities and partnerships.

This report helps executives to keep a track of their competitors and understand their pipeline molecules. The information presented in this report can be used for identifying the partners, prioritizing, evaluating opportunities, developing business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company and mechanism of action across the different stages of R&D. It includes registered / preregistered stage, phase 3 clinical trial, phase 2 clinical trial, phase 1 clinical trial, preclinical research, and drug discovery. It also provides information on pipeline molecules developed in leading geographies including the U.S., Canada, France, Germany, U.K., Italy, and Spain by various stages of R&D. Licensing activities and partnerships in the muscular atrophy drug market is thoroughly covered by company and licensee with the deal summary.

Key Features of the Report:
- Muscular Atrophy: Overview
- Muscular Atrophy Drug Pipeline Overview
- Muscular Atrophy Phase 3 Clinical Trial Drug Pipeline Insights
- Muscular Atrophy Phase 2 Clinical Trial Drug Pipeline Insights
- Muscular Atrophy Phase 1 Clinical Trial Drug Pipeline Insights
- Muscular Atrophy Preclinical Research Drug Pipeline Insights
- Muscular Atrophy Drug Discovery Pipeline Insights
- Geographic Landscape of Muscular Atrophy R&D Activities
- Muscular Atrophy R&D Activities in North America
- Muscular Atrophy R&D Activities in Europe
- Licensing Activities / Partnerships in the Global Muscular Atrophy Drug Market

1. Muscular Atrophy: Disease Definition
2. Muscular Atrophy Drug Pipeline Overview
3. Muscular Atrophy Phase 3 Clinical Trial Drug Pipeline Insights
4. Muscular Atrophy Phase 2 Clinical Trial Drug Pipeline Insights
5. Muscular Atrophy Phase 1 Clinical Trial Drug Pipeline Insights
6. Muscular Atrophy Preclinical Research Drug Pipeline Insights
7. Muscular Atrophy Drug Discovery Pipeline Insights
8. Geographic Landscape of Muscular Atrophy R&D Activities
8.1 Muscular Atrophy R&D Activities in North America
8.2 Muscular Atrophy R&D Activities in Europe
9 Licensing Activities / Partnerships in the Global Muscular Atrophy Drug Market
10 Research Methodology Table 1: Muscular Atrophy Drug Pipeline: Phase 3 Clinical Trial

Table 2: Muscular Atrophy Drug Pipeline: Phase 2 Clinical Trial
Table 3: Muscular Atrophy Drug Pipeline: Phase 1 Molecules
Table 4: Muscular Atrophy Drug Pipeline: Preclinical Research
Table 5: Muscular Atrophy R&D Activities by Geography
Table 6: Muscular Atrophy Drug Pipeline: North America
Table 7: Muscular Atrophy Drug Pipeline: Europe
Table 8: Muscular Atrophy Drug Pipeline: Licensing Activities

 Figure 1 : Muscular Atrophy Drug Pipeline Molecules by Stages
Figure 2 : Muscular Atrophy R&D Activities by Geography